Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Lorraine | OTHER |
| Cnam-ISTNA | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The research focuses on a follow-up measure of participants in the PRALIMAP-INÈS cohort (NCT01688453 - Legrand et al. 2017). PRALIMAP-INÈS was conducted between 2012 and 2015 with the objective of showing that adapted overweight support for less advantaged adolescents has an effect equivalent to standard support for advantaged adolescents in the short term. This trial included 3 measurement times: T0 (before intervention), T1 (after intervention, at the end of the school year), T2 (after intervention) and of the school year), T2 (one year later).
The proposed research is a continuation of PRALIMAP-INÈS with the addition of a 4th measurement time (T3) to study the trajectories of the intervention. (T3) to study the long-term social, economic, educational and health trajectories (in particular weight) of weight) of adolescents who have become young adults.
Beforehand, an information letter will be sent to the young adults included in PRALIMAP-INÈS at the postal and e-mail addresses initially provided. The objective is to present the study and to inform about the upcoming solicitation by the project team.
The young adults are contacted by a member trained in the project and the telephone call. This person will contact the young adults by phone to: follow up on the information letter, present the study to the young adult, verify the contact information from the T0, propose to fill out the questionnaire (T3) and propose to participate in a follow-up visit. The follow-up visit will take place in a medical center near the young adult's current place of residence, work or study. This visit will include a questionnaire as well as anthropometric measurements.
In addition to the data previously collected during follow-up visit 3, approximately 60 young adults will participate in a qualitative interview conducted by a sociologist. The goal is to gain a deeper understanding of the trajectories of young adults with respect to The objective is to gain a deeper understanding of the trajectories of young adults with respect to the social aspects that may affect health behavior. Dimensions such as educational and professional backgrounds, family and social networks, living conditions social networks, living conditions, etc. will be explored in detail.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Young adults who were included in the PRALIMAPINES trial as adolescents | The population is all young adults who were included in the PRALIMAPINES trial as adolescents (n=1419); we estimated 852 young adults participated in the follow-up visit (T3). This visit was proposed to investigate long-term social, economic, educational/professional and health (in particular weight) trajectories in adolescents in the PRALIMAP-INÈS intervention |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anthropometric measurements and sociodemographic and health data collection | Other | Anthropometric measurements : weight, height, abdominal circumference, abdominal circumference, percentage of fat mass, percentage of lean body mass, and estimated visceral fat level, visceral fat. Sociodemographic and health data collection : Collect over a 7-year period changes in physical activity practices, eating habits and behaviours and the motivations for these changes or the initiatives to change the weight, Perceived stress and control, Life courses, events and impact perception Status, level of education, social background, place of residence, relationship with family Diet, tobacco and alcohol consumptions Physical activity behaviour and barriers, sedentary behaviour, quality of life perceived, exploring possible behavioural eating disorders, anxiety, depression |
| Measure | Description | Time Frame |
|---|---|---|
| Evolution of the corpulence determined from the body mass index [BMI]. | Body Mass Index (BMI) indicates the ratio between your weight and your height in meters squared (kg/m^2). | Between visit of inclusion in PRALIMAP-INÉS trials (Time 0) and 7 years after the inclusion in PRALIMAP-INÉS trials (Time 3) |
| Measure | Description | Time Frame |
|---|---|---|
| Eating habits | Diet, tobacco and alcohol consumption (food frequency questionnaire (FNORS, 2009)) | Between visit of inclusion in PRALIMAP-INÉS trials (Time 0) and 7 years after the inclusion in PRALIMAP-INÉS trials (Time 3) |
| Physical activity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All adolescents included for PRALIMAP-INÈS will be asked to participate in this study (n=1419). Among the 1419 included PRALIMAP-INÈS participants, we estimate that 40% of 1419 will not contribute: 10% unknown address, 15% unsuccessfully contacted, and 15% refusal to participate. Estimating precisely the number of young adults who cannot be located will be difficult, because the cohort attrition rates are variable. However, the partnership with the regional education authority facilitated the follow-up and acquiring telephone details for young people who were mostly equipped with mobile phones when they were included in the PRALIMAP-INÈS trial and the implementation of young ambassadors will also be an opportunity for follow-up.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yacoubou OMOROU | Contact | 0383859303 | Y.OMOROU@chru-nancy.fr | |
| Mélanie BEGUINET | Contact | 0383851997 | dripromoteur@chru-nancy.fr |
| Name | Affiliation | Role |
|---|---|---|
| Yacoubou OMOROU | Central Hospital, Nancy, France | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHRU de Nancy | Recruiting | Nancy | 54000 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39266314 | Derived | Legrand K, Manneville F, Langlois J, Bohme P, Dosda A, Beguinet M, Briancon S, Spitz E, Lecomte E, Omorou AY. Ten-year postintervention follow-up of adolescents participating in the management of overweight and social inequalities (PRALIMAP-INES intervention): the PRALIMAP-CINeCO survey protocol. BMJ Open. 2024 Sep 12;14(9):e083090. doi: 10.1136/bmjopen-2023-083090. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D050177 | Overweight |
| D009765 | Obesity |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
Not provided
Not provided
Not provided
Not provided
Not provided
|
Physical activity and sedentary behaviour (GPAQ) (Rivière et al., 2018)
| Between visit of inclusion in PRALIMAP-INÉS trials (Time 0) and 7 years after the inclusion in PRALIMAP-INÉS trials (Time 3) |
| Anxiety, depression | Anxiety and depression (HAD) (Zigmond and Snaith, 1983) | Between visit of inclusion in PRALIMAP-INÉS trials (Time 0) and 7 years after the inclusion in PRALIMAP-INÉS trials (Time 3) |
| Level of quality of life | Quality of life (SF12) (Gandek et al., 1998) | Between visit of inclusion in PRALIMAP-INÉS trials (Time 0) and 7 years after the inclusion in PRALIMAP-INÉS trials (Time 3) |
| Educational/professional trajectories | Social statut (Family Affluence Scale [FAS] (Hartley et al., 2016)) | Between visit of inclusion in PRALIMAP-INÉS trials (Time 0) and 7 years after the inclusion in PRALIMAP-INÉS trials (Time 3) |
| Economic | Income | Between visit of inclusion in PRALIMAP-INÉS trials (Time 0) and 7 years after the inclusion in PRALIMAP-INÉS trials (Time 3) |
| Eating disorders | - Eating disorders (EAT-26) (Garner and Garfinkel, 1979): dieting, bulimia and food preoccupation and oral control | Between visit of inclusion in PRALIMAP-INÉS trials (Time 0) and 7 years after the inclusion in PRALIMAP-INÉS trials (Time 3) |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |